Genavia Therapeutics Licenses Technology from Origen Therapeutics, Inc. for Cost-Efficient Production of Human Therapeutics in Chicken Eggs

Published: Mar 09, 2009

EMERYVILLE, Calif. & AUCKLAND, New Zealand--(BUSINESS WIRE)--Origen Therapeutics of Emeryville, California and Genavia Therapeutics of Auckland, New Zealand today announced an agreement granting Genavia access to Origen’s transgenic technology for the production of therapeutic proteins in chicken eggs. The patent-protected technology has been shown capable of producing in egg whites high-value therapeutic proteins that are currently produced by expensive cell culture manufacturing processes. Financial details of the agreement were not disclosed.

Back to news